Patent classifications
C07H19/207
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
A compound of the structure: ##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N.SUP.6.-substituted purine nucleotides for HCV treatment
A compound of the structure: ##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N.SUP.6.-substituted purine nucleotides for HCV treatment
A compound of the structure: ##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
ASYMMETRIC AUXILIARY GROUP
To provide a chiral reagent or a salt thereof.
The chiral reagent has following chemical formula (I). In the formula (I), G.sup.1 and G.sup.2 are independently a hydrogen atom, a nitro group (NO.sub.2), a halogen atom, a cyano group (CN), a group of formula (II) or (III), or both G.sup.1 and G.sup.2 taken together to form a group of formula (IV).
##STR00001##
ASYMMETRIC AUXILIARY GROUP
To provide a chiral reagent or a salt thereof.
The chiral reagent has following chemical formula (I). In the formula (I), G.sup.1 and G.sup.2 are independently a hydrogen atom, a nitro group (NO.sub.2), a halogen atom, a cyano group (CN), a group of formula (II) or (III), or both G.sup.1 and G.sup.2 taken together to form a group of formula (IV).
##STR00001##
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N.SUP.6.-substituted purine nucleotides for HCV treatment
A compound of the structure: ##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N.SUP.6.-substituted purine nucleotides for HCV treatment
A compound of the structure: ##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
The present invention is directed to methods for the use of 5-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)
The present invention is directed to methods for the use of 5-adenosine diphosphate ribose (ADPR), and compositions thereof, for treating, managing, or preventing adenovirus-related diseases or conditions, eye disorders, cancer, or diseases or conditions caused by infection, inflammation, or physical, chemical, thermal, or radiation injuries.
BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
A compound of the structure:
##STR00001##
or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.